GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US. The programme represents the largest capital spend by ...

As a leading developer of vaccines, GSK has a part ... on setting up the vaccine manufacturing facility because it can take at least six years from the time the building commences to the time ...

The site at Ulverston currently belongs to GlaxoSmithKline ... manufacturing location". The proposals include "flexible office space" alongside refurbished laboratories, industrial buildings ...

In 2022, GSK’s 12 manufacturing sites in eight countries ... In addition to established platform technologies, GSK is building new platforms such as the Multiple Antigen-Presenting System ...

Taryn Paehr says that even in her earliest days as a student intern with GlaxoSmithKline Inc. (GSK), she realized the biopharmaceutical company offered the sort of workplace where she could grow ...

The firm is selling its Zinnat operation to Swiss-owned Sandoz, which will transfer manufacturing to its own plants in Austria. GSK's site in Ulverston, Cumbria, and its Zinnat buildings in ...

Workers at a number of GlaxoSmithKline manufacturing plants in the UK have voted to take industrial action over what the Unite union has described as a "derisory" pay offer. A majority of ...